Determinants of glucocorticoid dosing
- Daniel E Furst, MD
Daniel E Furst, MD
- Section Editor — Treatment Issues in Rheumatology
- Clinical professor, University of Washington, Seattle
- Clinical professor, University of Florence, Florence, Italy
- Professor of Rheumatology, University of California in Los Angeles (Emeritus)
- Director of Research, Pacific Arthritis Associates
- Kenneth G Saag, MD, MSc
Kenneth G Saag, MD, MSc
- Professor of Medicine
- University of Alabama at Birmingham
Natural and synthetic glucocorticoids (also called steroids) can be used for a variety of disorders. These agents are most commonly given in pharmacologic doses to manage conditions that require the suppression of inflammation. Less often, they are used to establish the diagnosis and cause of Cushing's syndrome and for hormone replacement in adrenal insufficiency and congenital adrenal hyperplasia.
The determinants of glucocorticoid dosing include:
●Pharmacokinetics of the different drug preparations
●Effects of underlying disorders on drug kinetics
●Interactions of glucocorticoids with concurrently administered non-glucocorticoid drugsTo continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Francisco GE, Honigberg IL, Stewart JT, et al. In vitro and in vivo bioequivalence of commercial prednisone tablets. Biopharm Drug Dispos 1984; 5:335.
- Lima JJ, Giller J, Mackichan JJ, Jusko WJ. Bioavailability of hydrocortisone retention enemas in normal subjects. Am J Gastroenterol 1980; 73:232.
- Garg DC, Wagner JG, Sakmar E, et al. Rectal and oral absorption of methylprednisolone acetate. Clin Pharmacol Ther 1979; 26:232.
- Elliott CL, Read GF, Wallace EM. The pharmacokinetics of oral and intramuscular administration of dexamethasone in late pregnancy. Acta Obstet Gynecol Scand 1996; 75:213.
- Hill MR, Szefler SJ, Ball BD, et al. Monitoring glucocorticoid therapy: a pharmacokinetic approach. Clin Pharmacol Ther 1990; 48:390.
- Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996; 97:169.
- Hale VG, Aizawa K, Sheiner LB, Benet LZ. Disposition of prednisone and prednisolone in the perfused rabbit liver: modeling hepatic metabolic processes. J Pharmacokinet Biopharm 1991; 19:597.
- Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 1981; 9:389.
- Legler UF, Frey FJ, Benet LZ. Prednisolone clearance at steady state in man. J Clin Endocrinol Metab 1982; 55:762.
- Wald JA, Law RM, Ludwig EA, et al. Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. J Pharmacokinet Biopharm 1992; 20:567.
- Meffin PJ, Wing LM, Sallustio BC, Brooks PM. Alterations in prednisolone disposition as a result of oral contraceptive use and dose. Br J Clin Pharmacol 1984; 17:655.
- Fisher LE, Ludwig EA, Wald JA, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm. Clin Pharmacol Ther 1992; 51:677.
- Sugita ET, Niebergall PJ. Bioavailability monograph: Prednisolone. J Am Pharm Assoc 1975; NS15:529.
- Theissen JJ. Bioavailability monograph: Prednisolone. J Am Pharm Assoc 1976; NS16:143.
- Reinberg A, Gervais P, Chaussade M, et al. Circadian changes in effectiveness of corticosteroids in eight patients with allergic asthma. J Allergy Clin Immunol 1983; 71:425.
- Brooks PM, Needs CJ. The use of antirheumatic medication during pregnancy and in the puerperium. Rheum Dis Clin North Am 1989; 15:789.
- Mortimer O, Grettve L, Lindström B, et al. Bioavailability of prednisolone in asthmatic patients with a poor response to steroid treatment. Eur J Respir Dis 1987; 71:372.
- Dove AM, Szefler SJ, Hill MR, et al. Altered prednisolone pharmacokinetics in patients with cystic fibrosis. J Pediatr 1992; 120:789.
- Frey FJ, Gambertoglio JG, Frey BM, et al. Nonlinear plasma protein binding and haemodialysis clearance of prednisolone. Eur J Clin Pharmacol 1982; 23:65.
- Sherlock JE, Letteri JM. Effect of hemodialysis on methylprednisolone plasma levels. Nephron 1977; 18:208.
- Zager PG, Spalding CT, Frey HJ, et al. Dialysance of adrenocorticoids during continuous ambulatory peritoneal dialysis. J Clin Endocrinol Metab 1988; 67:110.
- Frey FJ, Horber FF, Frey BM. Altered metabolism and decreased efficacy of prednisolone and prednisone in patients with hyperthyroidism. Clin Pharmacol Ther 1988; 44:510.
- Milsap RL, George DE, Szefler SJ, et al. Effect of inflammatory bowel disease on absorption and disposition of prednisolone. Dig Dis Sci 1983; 28:161.
- Frey FJ, Frey BM. Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. Am J Kidney Dis 1984; 3:339.
- Milsap RL, Plaisance KI, Jusko WJ. Prednisolone disposition in obese men. Clin Pharmacol Ther 1984; 36:824.
- Dunn TE, Ludwig EA, Slaughter RL, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 1991; 49:536.
- Lamiable D, Vistelle R, Sulmont V, et al. [Pharmacokinetics of dexamethasone administered orally in obese patients]. Therapie 1990; 45:311.
- Tsuei SE, Petersen MC, Ashley JJ, et al. Disporition of synthetic glucocorticoids. II. Dexamethasone in parturient women. Clin Pharmacol Ther 1980; 28:88.
- Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol 2004; 190:878.
- Renner E, Horber FF, Jost G, et al. Effect of liver function on the metabolism of prednisone and prednisolone in humans. Gastroenterology 1986; 90:819.
- Charlton M. Management of recurrence of hepatitis C infection following liver transplantation. Minerva Chir 2003; 58:717.
- Gary H. Wynn. Transplant surgery and rheumatology. In: Clinical manual of drug interaction principles for medical practice, 1st ed, Gary H. Wynn (Ed), APA Publishing Inc., Washington DC 2009. p.462.
- Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44:61.
- Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed Pharmacother 1986; 40:301.
- Boekenoogen SJ, Szefler SJ, Jusko WJ. Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab 1983; 56:702.
- Gustavson LE, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 1986; 62:234.
- Frey BM, Schaad HJ, Frey FJ. Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. Eur J Clin Pharmacol 1984; 26:505.
- LaForce CF, Szefler SJ, Miller MF, et al. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol 1983; 72:34.
- Szefler SJ, Brenner M, Jusko WJ, et al. Dose- and time-related effect of troleandomycin on methylprednisolone elimination. Clin Pharmacol Ther 1982; 32:166.
- Szefler SJ, Ellis EF, Brenner M, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. J Allergy Clin Immunol 1982; 69:455.
- Zürcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 1989; 45:366.
- Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther 1991; 49:558.
- Tanner AR, Caffin JA, Halliday JW, Powell LW. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Clin Pharmacol 1979; 7:397.
- Uribe M, Casian C, Rojas S, et al. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. Gastroenterology 1981; 80:661.
- Stjernholm MR, Katz FH. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. J Clin Endocrinol Metab 1975; 41:887.
- Frey FJ, Frey BM. Urinary 6 beta-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism. J Lab Clin Med 1983; 101:593.
- Brooks SM, Werk EE, Ackerman SJ, et al. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 1972; 286:1125.
- Frey BM, Frey FJ. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. Eur J Clin Invest 1984; 14:1.
- Evans PJ, Walker RF, Peters JR, et al. Anticonvulsant therapy and cortisol elimination. Br J Clin Pharmacol 1985; 20:129.
- Petereit LB, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther 1977; 22:912.
- Frey FJ, Lozada F, Guentert T, Frey BM. A single dose of azathioprine does not affect the pharmacokinetics of prednisolone following oral prednisone. Eur J Clin Pharmacol 1981; 19:209.
- Frey FJ, Schnetzer A, Horber FF, Frey BM. Evidence that cyclosporine does not affect the metabolism of prednisolone after renal transplantation. Transplantation 1987; 43:494.
- Glynn-Barnhart AM, Erzurum SC, Leff JA, et al. Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. J Allergy Clin Immunol 1991; 88:180.
- Sirgo MA, Rocci ML Jr, Ferguson RK, et al. Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. Clin Pharmacol Ther 1985; 37:534.
- Brooks SM, Sholiton LJ, Werk EE Jr, Altenau P. The effects of ephedrine and theophylline on dexamethasone metabolism in bronchial asthma. J Clin Pharmacol 1977; 17:308.
- BIOEQUIVALENCE AND BIOAVAILABILITY
- Inhaled glucocorticoids
- Distribution in breast milk
- DISEASES AND ALTERED PHYSIOLOGIC STATES
- Cystic fibrosis
- End-stage renal disease
- Inflammatory bowel disease
- Nephrotic syndrome
- Severe liver disease
- DRUG INTERACTIONS
- Systemic glucocorticoids
- Inhaled or intranasal glucocorticoids
- SUMMARY AND RECOMMENDATIONS